These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8600659)

  • 1. [Osteoporosis. 2].
    Fojtík Z; Mayer J
    Vnitr Lek; 1995 Dec; 41(12):851-7. PubMed ID: 8600659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Differential therapy of osteoporosis--an overview based on recent findings regarding the pathogenesis].
    Schacht E
    Z Rheumatol; 1994; 53(5):274-98. PubMed ID: 7810237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
    Epstein S
    Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
    Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The interest of biochemical markers of bone turnover for monitoring treatment of postmenopausal osteoporosis].
    Kalaï E; Bahlous A; Makdouli A; Sahli H; Klouz A; Lakhal M; Sellami S; Abdelmoula J
    Tunis Med; 2008 Feb; 86(2):122-7. PubMed ID: 18444527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Postmenopausal osteoporosis].
    László A
    Orv Hetil; 2004 Jan; 145(1):3-13. PubMed ID: 15222134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biochemical markers of bone turnover : clinical usefulness in osteoporosis].
    Garnero P; Delmas PD
    Ann Biol Clin (Paris); 1999; 57(2):137-48. PubMed ID: 10210740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A
    Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
    Shaarawy M; Zaki S; Sheiba M; El-Minawi AM
    Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoporotic compression fractures of the spine; current options and considerations for treatment.
    Kim DH; Vaccaro AR
    Spine J; 2006; 6(5):479-87. PubMed ID: 16934715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
    Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P
    Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to pharmacological treatment of osteoporosis.
    Akesson K
    Bull World Health Organ; 2003; 81(9):657-64. PubMed ID: 14710507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug treatment of osteoporosis (in the woman)].
    Ziegler R
    Ther Umsch; 1998 Nov; 55(11):696-701. PubMed ID: 9865146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoporosis: new hope for the future.
    Masi L; Bilezikian JP
    Int J Fertil Womens Med; 1997; 42(4):245-54. PubMed ID: 9309458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis: drug and nondrug therapies for the patient at risk.
    Gamble CL
    Geriatrics; 1995 Aug; 50(8):39-43. PubMed ID: 7635326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.